Development of a unified DMPK and CNBP PCR workflow for determining repeat expansions relevant to myotonic dystrophies

Jacob Wisotsky, Jon Kemppainen, Vivian Le, Gary J Latham, and Bradley Hall Asuragen, Inc., Austin, Texas, USA

Summary

- Myotonic dystrophy (DM) is the most common adult-onset muscular dystrophy. Type 1 is caused by an expansion of CTG in DMPK while Type 2 is caused by an expansion of CCTG in CNBP.
- Both diseases have similar presentation making differentiation important.
- The repeat regions of both DMPK and CNBP are extremely challenging to amplify and resolve using PCR.
- Here we demonstrate a unified workflow to genotype at least 200 CTG repeats in DMPK and flag expansions of >75 CCTG repeats in CNBP.

Introduction

Myotonic dystrophy type 1 and 2 (DM1 and DM2) are the most prevalent adult-onset muscular dystrophies. DM1 is caused by a trinucleotide expansion of CTG in the 3' untranslated region (UTR) of myotonic dystrophy protein kinase (DMPK). Clinical phenotypes manifest in patients who have >50 repeats with classic disease occurring in those with >100 repeats. DM2 is caused by a quadruplet nucleotide expansion of CCTG in intron 1 of the cellular nucleic acid-binding protein (CNBP). Pathogenicity is observed in those with >75 repeats. Expansions in the DM2 disease state can be between 75-11,000 repeats; however, the average is 5,000. In both cases, expansions often include hundreds to thousands of repeat units. DM1 and DM2 molecular diagnosis relies on a complex combination of PCR and Southern blot analysis. Due to a set of overlapping symptoms, DM1 and DM2 can be part of the same differential diagnosis. Current methods fail to identify expansions in DMPK and CNBP using a streamlined assay format. Thus we have proposed a workflow that unifies the determination of an expansion occurring in either DMPK or CNBP.



Figure 1. DMPK Gene Map and CNBP Gene Map. A) DM1 is caused by the expansion of the trinucleotide repeat CTG in the 3' UTR of the DMPK gene which is found on chromosome 19. As shown, 5-37 repeats is considered normal. Anticipation is observed when the repeat length reaches between 38-49 and a set of mild disease phenotypes occurs when the expansion reaches between 50-150 repeats. Classical DM1 is associated with more than 150 repeats and full congenital DM1 beyond 1000 repeats which can result in more severe symptoms and early death. B) DM2 is caused by an expansion of CCTG in intron 1 of CNBP on chromosome 3. Unlike DM1, DM2 has less specificity in the diagnostic applicability of the number of repeats. Normal individuals can carry up to 75 repeats but often far less (between 1-30). Disease occurs when an individual has 75 or more repeats.

Materials and Methods

A streamlined DMPK/CNBP assay and workflow was developed with prototype AmplideX® PCR/ CE reagents optimized for the repeat-primed amplification of both DMPK and CNBP repeats using distinct dye-tagged primers. Sample gDNAs were amplified in separate PCR reactions for DMPK and CNBP on the same PCR plate. Amplicons were resolved on a 3500xL Genetic Analyzer CE instrument (Thermo Fisher) using POP7 polymer, with 2.5 kV, 20 sec injection and 40 min run time. Samples for Figure 6 were multiplexed post PCR and run on the CE. Genotyping for DMPK was achieved following sizing analysis using a ROX 1000 size ladder (Asuragen) and a four-point calibrator. Sanger sequencing was accomplished by cloning purified gene-specific DMPK PCR product into a vector and then screening for inserts via colony PCR. Vectors containing inserts were then sequenced.



Figure 2. DMPK/CNBP PCR/CE Workflows. A) The majority of data for Figure 3, Figure 4, and Table 1 were generated using the framework depicted. This singleplex workflow allows samples to be run on the same plate in the thermocycler and by CE. B) The assay can also be performed in separate thermocycling reactions but on the same plate, yet multiplexed during CE injection. This methodology was used to generate Figure 6. C) Further, it may be possible to fully multiplex this assay into a single-tube PCR and single CE injection.



Figure 3. Representative DMPK PCR/CE Results. A) Coriell sample NA23355 with normal genotype (13 and 25 CTG repeats shown in green text by gene-specific amplicons). B) NA06075 with *DMPK* genotype containing a normal allele plus mosaic expanded alleles greater than 50 repeats (12, 55, 70). C) NA23356 with *DMPK* genotype of 25, expanded include mosaic alleles at 101 and 135 repeats plus evidence of an expanded allele with >200 repeats. D) NA03132 with DMPK full classic genotype (5, expanded) without mosaicism detectable >200 repeats



Sample	DMPK Allele 1	DMPK Allele 2	CNBP Status			DMPK Allele 1	DMPK Allele 2	CNBP Status
NA03132	5	>200	Normal		RS03127	5		Normal
NA03696	12	>200	Normal		RS03128	12	13	Normal
NA03697	12	>200	Normal	1	RS03129	12		Normal
NA03756	13	>200	Normal		RS03130	5	13	Normal
NA03759	14	>200	Normal		RS03131	5	29	Normal
NA03991	14	110, >200	Normal		RS03132	14		Normal
NA04567	21	>200	Normal	1	RS03133	5	14	Normal
NA04648	5	>200	Normal	1	RS03134	5	13,14	Normal
NA05152	21	>200	Normal	1	RS03135	5	12	Normal
NA05164	5	>200	Normal	1	RS03136	5	15	Normal
NA06075	12	55,70	Normal		RS03137	12	14	Normal
NA23256	25	101, 135, >200	Normal		RS03138	5	13	Normal
NA23265	12	63, 75	Normal	1	RS03139	13	14	Normal
NA23299	22	>200	Normal	1	RS03140	5	15	Normal
NA23300	5	>200	Normal	1	RS03141	5	14	Normal
NA23378	22	75, 127	Normal	1	RS03142	12		Normal
NA23259	12	22	Expanded	1	RS03143	5	12	Normal
NA23355	13	25	Expanded	1	RS03144	12	14	Normal
NA23376	20	22	Expanded	1	RS03145	5	13	Normal
NG12729	5	21	Expanded	1	RS03170	15	22	Normal

Table 1. DMPK and CNBP Genotypes for 40 Samples. Samples in bold orange text are also presented in Figure 3 or 4. The prototype DMPK assay identified 16/16 previously-reported expansions, 13 of which had expansions of 100 or more repeats. The prototype CNBP assay correctly flagged 4/4 previously-characterized samples and identified 36 samples as normal genotype including 16 Coriell DMPK samples and 20 normal healthy volunteers. Samples with greater than 75 repeats are reported as expanded.



Figure 5. Comparison of CNBP PCR/CE Electropherograms Traces with Sanger Sequencing Results. A) CE trace for NA23265, a homozygous normal sample. Above the CE trace is the consensus sequence we obtained from Sanger sequencing the CNBP locus. This sequence contains the standard interruption pattern that is characteristic of normal samples. B) CE trace for NA23376, a heterozygous expanded sample. The normal allele contains the standard interruption pattern whereas the expanded allele can be observed extending well beyond the primary peak pattern.



Figure 6. Unified DMPK/CNBP Workflow Output. A) CE trace for NA03132, a sample with unexpanded CNBP but expanded DMPK. B) The bottom two figures depict the deconvolved CE results with the DMPK expansion in the FAM (blue) channel and unexpanded CNBP in the HEX (green) channel.

Conclusions

- Prototype DMPK and CNBP PCR/CE assays demonstrated highly resolved repeat-specific signals, repeatable results, and accurate categorical classifications.
- The DMPK PCR/CE assay detected 16/16 samples with repeat expansions in agreement with published data, as well as expected results with presumed normal samples.
- The CNBP PCR/CE assay identified 4 expanded

*Proof-of-concept data only Presented at ASHG 2017

Figure 4. Representative CNBP PCR/CE Results. A) Coriell sample NA03132 with a normal CNBP genotype. The observed (CCTG)_n repeat peaks show combined readout for both alleles. Non-expanded alleles typically manifest as taller peaks in the leftmost region of the profile. The largest allele detected in this region is indicated with a star. The blue arrow indicates an interruption pattern (typically seen in normal samples). B-D) Samples with expanded CNBP genotypes. Assay output for these samples show (CCTG)_n repeat peaks for both the normal and expanded allele in each case where the last detectable normal peak is indicated with a star, and the 100th repeat peak is indicated with an asterisk for expanded alleles.

- samples and 36 unexpanded samples, consistent with expectation.
- The CNBP PCR/CE assay revealed interruption patterns in both normal and expanded samples.

References

- References
 1. Kansteg, E. J., Kress, W., Catalli, C., Hertz, J. M., Witsch-Baumgartner, M., Buckley, M. F., et al. (2012). Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. European Journal of Human Genetics: EJHG, 20(12), 1020-8. http://doi.org/10.1038/ejhg.2012.108
 2. Bachinski, L. L., Czernuszewicz, T., Ramagil, L. S., Suominen, T., Shriver, M. D., Udd, B., et al. (2009). Premutation allele pool in myotonic dystrophy type 2. Neurology, 72(6), 490-497. http://doi.org/10.1212/01.wnl.000033665.01888.33
 2. Datton, J. C., Ranun, L. P., Ba Day, J. W. (1993). Myotonic Dystrophy Type 2. GeneReviews*. University of Washington, Seattle. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20301639
 4. Prior T. W., American College of Medical Genetics (ACMG) Laboratory Quality Assurance Committee (2009) Technical standards and guidelines for myotonic dystrophy type 1 testing. Genet Med 11:552-555. doi: 10.1097/GIM.00013e3161a6ceff
 S.avić Pavićević D., Mitadinović J., Brkušanin M., et al. (2013) Molecular Genetics and Genetic Testing in Myotonic Dystroph Type 1. Biomed Res Int 2013:1-13. doi: 10.1155/2013/391821

